Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Oct 3, 2024
Greg Sturmer, Co-Founder and CEO of Elysium Therapeutics, a company with expertise in reducing pain and addressing opioid use disorder and fatal overdose from fentanyl. Elysium has developed O2P, Oral Overdose Protection, a technology that aims to control the impact of opioids and reduce the risk of use disorder or a fatal overdose. SOOPR is a rescue agent designed specifically for overdoses from synthetic opioids, particularly fentanyl, which can last longer and be more potent than traditional opioids.
Greg explains, "Anytime there’s an epidemic, you want to control exposure. The tricky bit in the area of pain management and the use of opioids is how do you control exposure without affecting patient care. We’ve come up with a technology that maintains the unmatched efficacy of the opioids. But when somebody takes too many pills, and we’ve actually shown this in our human study, we can reduce the exposure because we use this proprietary molecular delivery system that uses the body’s natural digestive process to control how much of the opioid gets released. That’s how we’re addressing the front end of the issue, where somebody is prescribed an opioid."
"But sadly, what happens today is several individuals progress along the road to opioid use disorder, and they end up using illicit drugs. That’s where our second program, SOOPR, comes into play. As you know, our streets in the US have been flooded with fentanyl. Fentanyl is a highly potent opioid. The cartels have gotten very wise in how to expand their market. They introduced fentanyl-laced pills because a lot more people are willing to take pills rather than inject. Well, that changed the game dramatically because when somebody overdoses orally on fentanyl, that puts them at risk of respiratory depression for hours where they stop breathing."
"Existing rescue agents like Narcan and Opvee weren’t designed for oral synthetic opioids and overdoses of those drugs. SOOPR, we believe, is the first rescue agent designed specifically for synthetic opioids. What it does is it outlasts that synthetic opioid danger zone, blocking the mu-opioid receptors and preventing that respiratory depression or rescuing somebody who’s already in respiratory depression."
#ElysiumTherapeutics #Opioids #OpioidAbuse #SyntheticOpioids #OpioidUseDisorder #PainManagement #SaferMedicines
